Baxter Opens First Biologics Facility in Asia

Aug 07, 2014

Baxter International Inc. officially opened its first advanced recombinant biologic facility in Singapore. The company also announced expansion plans for a new recombinant protein processing suite. The facility and new investment will have created 450 biopharmaceutical jobs by 2015 in Singapore.

Baxter said in a press release that the current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the market leading full-length recombinant factor VIII (rFVIII) worldwide for the treatment of patients with hemophilia A. The second suite will initially process RIXUBIS [Coagulation Factor IX (Recombinant)]2, a recombinant factor IX (rFIX) protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval.

Speaking at the opening of the facility, Jean-Luc Butel, corporate vice president and president of Baxter's international operations, said, "As a long-standing, established leader in the global hemophilia community, Baxter has focused efforts on improving standards of care for people with hemophilia. The opening of the Singapore facility is a reflection of the company's commitment."

Read the full press release

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments